1673MO - The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management

Background

The novel COVID-19 outbreak spread rapidly around the world. Cancer patients (pts) consist of a highly vulnerable group due to underlying malignancy and/or treatment-induced immunosuppression. A high mortality rate from COVID-19 in cancer pts was previously reported. France is the fourth most affected country, with more than 150,000 infected individuals and over 28,000 deaths. GCO-002 CACOVID-19 study is a large French nationwide cohort of COVID-19 pts with solid tumors with the aim to identify risk factors of COVID-19 severity and evaluate impact on cancer treatment.

Methods

Bispective multicenter cohort set up by the French Cooperative Groups in solid cancers: ANOCEF-IGCNO (CNS tumors), ARCAGY-GINECO (gynecological and breast cancers), FFCD (digestive cancers), GERCOR (digestive and other solid cancers), GORTEC/intergroupe ORL (head and neck cancers (H&N), and IFCT (thoracic cancers). French pts with solid cancers and COVID-19 diagnosed since 1 March 2020 were accrued. Exclusion criteria: pts treated curatively > 5 years ago.

Results

From 6 April to 15 May 2020, 835 pts from 136 institutions (general hospitals 35%, university hospitals 35%, private centers 25%, cancer centers 5%) were registered. Men: 61%, median age: 69 years (20-100). Digestive cancers: 43% (16%/9% colorectal/pancreatic cancers), lung cancers: 22%, gynecological: 14%, (9% breast cancers), H&N: 10%, CNS: 4%, urologic cancers: 3%. Advanced or metastatic: 61%. Within 3 months before COVID-19 diagnosis, 69% of pts received a systemic anticancer treatment (chemotherapy, targeted or immune therapy) and 22% a local therapy (surgery, radiotherapy or local destruction). Diagnosis of COVID-19 was confirmed by RT-PCR, CT-scan or both in 91% or serology in 1.4%. COVID was treated in the same oncological center in 78%. During the follow-up period (mean 14 days), 208 (25%) pts died, including 173 (21%) COVID-19 related deaths.

Conclusions

This first nationwide study of cancer pts with COVID-19 from France reports a high mortality rate. Updated and detailed data on anti-cancer treatments, risk factors of severe and fatal COVID-19 and impact of COVID-19 on cancer management will be presented.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Fédération Francophone de Cancérologie Digestive.

Funding

Has not received any funding.

Disclosure

A. Lièvre: Honoraria (self), Advisory/Consultancy: AAA; Amgen, Pierre Fabre; Sandoz; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bayer; Novartis; Honoraria (self): Celgene; HalioDx; Lilly; Honoraria (self), Travel/Accommodation/Expenses: BMS; Roche; Honoraria (self), Research grant/Funding (self): Incyte; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Merck; Servier; Research grant/Funding (self): Integragen; Travel/Accommodation/Expenses: AAA; Pfizer. A. Turpin: Honoraria (self): Servier; Advisory/Consultancy: Mylan; Merck Serono; Amgen; Travel/Accommodation/Expenses: Merck; Sanofi; Pfizer; AstraZeneca. I.L. Ray-Coquard: Honoraria (self), Advisory/Consultancy: Abbvie; Agenus; Advaxis; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): BMS; MSD; Honoraria (self), Advisory/Consultancy: PharmaMar; Genmab; Pfizer; Deciphera; Mersena; Amgen; Tesaro; Clovis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: GSK; Non-remunerated activity/ies: GINECO; ENGOT; GCIG; European community; ESMO; ASCO; ESGO; IGSC; Inca; Swiss and German Health Authorities; Italian Health Authority; Belgium Health Authority. J. Thariat: Honoraria (self): BMS; Honoraria (institution), Travel/Accommodation/Expenses, Full/Part-time employment: Centre François Baclesse; Leadership role: President of the French Head and Neck Intergroup, GORTEC secretary; Non-remunerated activity/ies: Director of Easy-CRF society; Research grant/Funding (institution): Nanobiotix. G. Ahle: Travel/Accommodation/Expenses: Abbvie; Biogen; Novartis; Roche; Sanofi; Non-remunerated activity/ies: ANOCEF; NENO; AlSacEP. R. Mathieu: Honoraria (self), Research grant/Funding (self): Astellas; Honoraria (self): AstraZeneca; Ferring; Ipsen; Janssen; MSD; Pfizer; Sanofi; Takeda. D. Debieuvre: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Roche; Novartis; BMS; MSD; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Research grant/Funding (institution): Chugaï; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Boerhinger-Ingelheim; Research grant/Funding (institution): Chiesi; Sandoz; Takeda; GSK; Research grant/Funding (self): Lilly. A. Canellas: Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Oxyvie; LVL Medical; Boerhinger Ingelheim. A-C. Hardy-Bessard: Advisory/Consultancy: Clovis; Novartis; Roche; MSD; AstraZeneca; GSK. L. Mansi: Honoraria (institution), Advisory/Consultancy: Sandoz; Advisory/Consultancy: Roche; Eisai; Pfizer; Novartis; Speaker Bureau/Expert testimony: Exact Sciences; Travel/Accommodation/Expenses: Lilly. P. Gorphe: Honoraria (self): Intuitive Surgical; Non-remunerated activity/ies: Chair, scientific board, French Head and Neck Intergroup; Research grant/Funding (institution): MSD. A. IDBAIH Ahmed: Research grant/Funding (institution): Transgene; Sanofi; Air Liquide; Travel/Accommodation/Expenses: Carthera; Leo Pharma. G. Zalcman: Honoraria (self), Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (institution): Takeda; Travel/Accommodation/Expenses: Pfizer; AbbVie; MSD. O. Bouche: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Merck KgaA; Bayer; AstraZeneca; Grunenthal; MSD; Honoraria (self), Speaker Bureau/Expert testimony: Amgen; Pierre Fabre;Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Servier. All other authors have declared no conflicts of interest.